Tag: GlobeNewswire

Selections by one of the largest state court systems in the country and a state department of corrections expand HEXWAVE’s reach across the company’s priority markets

WILMINGTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (NASDAQ: DETX; TSXV: SCAN), a leading provider of AI-based, next-generation detection solutions for concealed weapons and threats, today announced that HEXWAVE™ has been selected by one of the largest state court systems in the country and by a state department of corrections. The combined initial awards for four HEXWAVE’s™ will be deployed at the various sights over the next few months.

The court system will deploy HEXWAVE at an active courthouse in the first phase of a program whose results could lead to consideration at additional facilities. Court personnel, jurors and the public share one entrance, and threats now include non-metallic weapons such as ceramic knives and 3D-printed guns.

The corrections award covers three facilities under one department, including one scheduled to open in 2027 with screening built into its design. Staff, residents and visitors pass through controlled entrances, much of the contraband officers look for is not metal, and HEXWAVE screens without physical contact.

Both selections follow Liberty’s September 16 announcement of a multi-site agreement with a third-party logistics, warehousing and manufacturing provider, which marked the company’s entry into commercial loss prevention. Together they add to a footprint that already spans aviation, government buildings, courthouses, correctional facilities and commercial venues, including nine airports for aviation worker screening. HEXWAVE is deployed at approximately 20 sites in five countries, with more than 40 units in the field.

“Courts, corrections and loss prevention each have their own reason to screen,” said Bill Frain, CEO of Liberty Defense. “A courthouse is focused on public safety, a corrections department on contraband and a distribution operation on inventory loss, and HEXWAVE fits all three entrances. Every selection gives us a model for similar operators. These recent announcements align with our market vertical focus of protecting people and assets for aviation worker screening, courthouses, correctional facilities and loss prevention.”

HEXWAVE detects metallic and non-metallic threats and contraband concealed on people, including liquids, powders and vapes, using millimeter wave technology and AI-based automatic threat detection. The operator sees a generic body outline marking where an item was detected, and HEXWAVE stores no images or personal information. It is designed as one layer of a site’s security program.

For updates and news, please visit the Company website to subscribe to email alerts or follow Liberty Defense on social channels.

On Behalf of Liberty Defense
Bill Frain
CEO & Director

About Liberty Defense
Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (NASDAQ: DETX; TSXV: SCAN) provides multi-technology security solutions for concealed weapons detection in high volume foot traffic areas and locations requiring enhanced security in public places. Liberty’s HEXWAVE product, for which the company has secured an exclusive license from Massachusetts Institute of Technology (MIT), as well as a technology transfer agreement for patents related to active 3D radar imaging technology, provides discrete, modular, and scalable protection to provide layered, stand-off detection capability of metallic and non-metallic weapons. Liberty has also recently licensed the millimeter wave-based, High-Definition Advanced Imaging Technology (HD-AIT) body scanner and shoe scanner technologies as part of its technology portfolio. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions. Learn more: LibertyDefense.com
For sales information, please contact:

Ian McNaughton
Senior Director Business Development, Liberty Defense
613-292-3669
imcnaughton@libertydefense.com

FORWARD-LOOKING STATEMENTS
When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because Liberty can give no assurance that such statements will prove to be correct. Such statements and information reflect the current view of Liberty.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. There are a number of important factors that could cause Liberty’s actual results to differ materially from those indicated or implied by forward-looking statements and information, including those appearing in Liberty’s public filings. Such factors include, among others: currency fluctuations; limited business history of the parties; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses; general development, market and industry conditions; and other factors described in Liberty’s public filings. The parties undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of their securities or their respective financial or operating results (as applicable).

Liberty cautions that the foregoing list of material factors is not exhaustive. When relying on Liberty’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Liberty has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of Liberty as of the date of this press release and, accordingly, are subject to change after such date. Liberty does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Selections by one of the largest state court systems in the country and a state department of corrections expand HEXWAVE’s reach across the company’s priority markets

WILMINGTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (NASDAQ: DETX; TSXV: SCAN), a leading provider of AI-based, next-generation detection solutions for concealed weapons and threats, today announced that HEXWAVE™ has been selected by one of the largest state court systems in the country and by a state department of corrections. The combined initial awards for four HEXWAVE’s™ will be deployed at the various sights over the next few months.

The court system will deploy HEXWAVE at an active courthouse in the first phase of a program whose results could lead to consideration at additional facilities. Court personnel, jurors and the public share one entrance, and threats now include non-metallic weapons such as ceramic knives and 3D-printed guns.

The corrections award covers three facilities under one department, including one scheduled to open in 2027 with screening built into its design. Staff, residents and visitors pass through controlled entrances, much of the contraband officers look for is not metal, and HEXWAVE screens without physical contact.

Both selections follow Liberty’s September 16 announcement of a multi-site agreement with a third-party logistics, warehousing and manufacturing provider, which marked the company’s entry into commercial loss prevention. Together they add to a footprint that already spans aviation, government buildings, courthouses, correctional facilities and commercial venues, including nine airports for aviation worker screening. HEXWAVE is deployed at approximately 20 sites in five countries, with more than 40 units in the field.

“Courts, corrections and loss prevention each have their own reason to screen,” said Bill Frain, CEO of Liberty Defense. “A courthouse is focused on public safety, a corrections department on contraband and a distribution operation on inventory loss, and HEXWAVE fits all three entrances. Every selection gives us a model for similar operators. These recent announcements align with our market vertical focus of protecting people and assets for aviation worker screening, courthouses, correctional facilities and loss prevention.”

HEXWAVE detects metallic and non-metallic threats and contraband concealed on people, including liquids, powders and vapes, using millimeter wave technology and AI-based automatic threat detection. The operator sees a generic body outline marking where an item was detected, and HEXWAVE stores no images or personal information. It is designed as one layer of a site’s security program.

For updates and news, please visit the Company website to subscribe to email alerts or follow Liberty Defense on social channels.

On Behalf of Liberty Defense
Bill Frain
CEO & Director

About Liberty Defense
Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (NASDAQ: DETX; TSXV: SCAN) provides multi-technology security solutions for concealed weapons detection in high volume foot traffic areas and locations requiring enhanced security in public places. Liberty’s HEXWAVE product, for which the company has secured an exclusive license from Massachusetts Institute of Technology (MIT), as well as a technology transfer agreement for patents related to active 3D radar imaging technology, provides discrete, modular, and scalable protection to provide layered, stand-off detection capability of metallic and non-metallic weapons. Liberty has also recently licensed the millimeter wave-based, High-Definition Advanced Imaging Technology (HD-AIT) body scanner and shoe scanner technologies as part of its technology portfolio. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions. Learn more: LibertyDefense.com
For sales information, please contact:

Ian McNaughton
Senior Director Business Development, Liberty Defense
613-292-3669
imcnaughton@libertydefense.com

FORWARD-LOOKING STATEMENTS
When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because Liberty can give no assurance that such statements will prove to be correct. Such statements and information reflect the current view of Liberty.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. There are a number of important factors that could cause Liberty’s actual results to differ materially from those indicated or implied by forward-looking statements and information, including those appearing in Liberty’s public filings. Such factors include, among others: currency fluctuations; limited business history of the parties; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses; general development, market and industry conditions; and other factors described in Liberty’s public filings. The parties undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of their securities or their respective financial or operating results (as applicable).

Liberty cautions that the foregoing list of material factors is not exhaustive. When relying on Liberty’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Liberty has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of Liberty as of the date of this press release and, accordingly, are subject to change after such date. Liberty does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Selections by one of the largest state court systems in the country and a state department of corrections expand HEXWAVE’s reach across the company’s priority markets

WILMINGTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (NASDAQ: DETX; TSXV: SCAN), a leading provider of AI-based, next-generation detection solutions for concealed weapons and threats, today announced that HEXWAVE™ has been selected by one of the largest state court systems in the country and by a state department of corrections. The combined initial awards for four HEXWAVE’s™ will be deployed at the various sights over the next few months.

The court system will deploy HEXWAVE at an active courthouse in the first phase of a program whose results could lead to consideration at additional facilities. Court personnel, jurors and the public share one entrance, and threats now include non-metallic weapons such as ceramic knives and 3D-printed guns.

The corrections award covers three facilities under one department, including one scheduled to open in 2027 with screening built into its design. Staff, residents and visitors pass through controlled entrances, much of the contraband officers look for is not metal, and HEXWAVE screens without physical contact.

Both selections follow Liberty’s September 16 announcement of a multi-site agreement with a third-party logistics, warehousing and manufacturing provider, which marked the company’s entry into commercial loss prevention. Together they add to a footprint that already spans aviation, government buildings, courthouses, correctional facilities and commercial venues, including nine airports for aviation worker screening. HEXWAVE is deployed at approximately 20 sites in five countries, with more than 40 units in the field.

“Courts, corrections and loss prevention each have their own reason to screen,” said Bill Frain, CEO of Liberty Defense. “A courthouse is focused on public safety, a corrections department on contraband and a distribution operation on inventory loss, and HEXWAVE fits all three entrances. Every selection gives us a model for similar operators. These recent announcements align with our market vertical focus of protecting people and assets for aviation worker screening, courthouses, correctional facilities and loss prevention.”

HEXWAVE detects metallic and non-metallic threats and contraband concealed on people, including liquids, powders and vapes, using millimeter wave technology and AI-based automatic threat detection. The operator sees a generic body outline marking where an item was detected, and HEXWAVE stores no images or personal information. It is designed as one layer of a site’s security program.

For updates and news, please visit the Company website to subscribe to email alerts or follow Liberty Defense on social channels.

On Behalf of Liberty Defense
Bill Frain
CEO & Director

About Liberty Defense
Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (NASDAQ: DETX; TSXV: SCAN) provides multi-technology security solutions for concealed weapons detection in high volume foot traffic areas and locations requiring enhanced security in public places. Liberty’s HEXWAVE product, for which the company has secured an exclusive license from Massachusetts Institute of Technology (MIT), as well as a technology transfer agreement for patents related to active 3D radar imaging technology, provides discrete, modular, and scalable protection to provide layered, stand-off detection capability of metallic and non-metallic weapons. Liberty has also recently licensed the millimeter wave-based, High-Definition Advanced Imaging Technology (HD-AIT) body scanner and shoe scanner technologies as part of its technology portfolio. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions. Learn more: LibertyDefense.com
For sales information, please contact:

Ian McNaughton
Senior Director Business Development, Liberty Defense
613-292-3669
imcnaughton@libertydefense.com

FORWARD-LOOKING STATEMENTS
When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because Liberty can give no assurance that such statements will prove to be correct. Such statements and information reflect the current view of Liberty.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. There are a number of important factors that could cause Liberty’s actual results to differ materially from those indicated or implied by forward-looking statements and information, including those appearing in Liberty’s public filings. Such factors include, among others: currency fluctuations; limited business history of the parties; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses; general development, market and industry conditions; and other factors described in Liberty’s public filings. The parties undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of their securities or their respective financial or operating results (as applicable).

Liberty cautions that the foregoing list of material factors is not exhaustive. When relying on Liberty’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Liberty has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of Liberty as of the date of this press release and, accordingly, are subject to change after such date. Liberty does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY^® Endovascular Robotic System Throughout Israel

Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.

HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company’s LIBERTY System in Israel. The Company received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, and was registered in the Israeli Medical Device Registry (AMAR) in May 2026. The Company anticipates initial orders from Medtechnica Ltd. under the agreement during the fourth quarter of 2026.

“We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel,” commented Harel Gadot, CEO, President and Chairman. “This is an important milestone for us and is expected to lead to hospitals and physicians in Israel gaining access to the LIBERTY System and achieving the same positive experiences our U.S.-based customers are enjoying. Looking ahead, we anticipate entering new markets and adding further strategic distribution partners as we continue to scale our operations, expand our manufacturing capacity, and position Microbot to meet growing demand across both U.S. and international markets.”

“We are proud to partner with Microbot Medical and bring the LIBERTY Endovascular Robotic System to the Israeli endovascular market,” said Ravit Kremer, CEO of Medtechnica Ltd. “This agreement reflects Medtechnica’s ongoing commitment to introducing innovative medical technologies that can support physicians, advance clinical practice and improve patient care. With our strong presence and experience in the endovascular field, we look forward to working closely with Microbot Medical to introduce LIBERTY to leading hospitals and clinical teams across Israel.”

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements pertaining to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY^® Endovascular Robotic System Throughout Israel

Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.

HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company’s LIBERTY System in Israel. The Company received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, and was registered in the Israeli Medical Device Registry (AMAR) in May 2026. The Company anticipates initial orders from Medtechnica Ltd. under the agreement during the fourth quarter of 2026.

“We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel,” commented Harel Gadot, CEO, President and Chairman. “This is an important milestone for us and is expected to lead to hospitals and physicians in Israel gaining access to the LIBERTY System and achieving the same positive experiences our U.S.-based customers are enjoying. Looking ahead, we anticipate entering new markets and adding further strategic distribution partners as we continue to scale our operations, expand our manufacturing capacity, and position Microbot to meet growing demand across both U.S. and international markets.”

“We are proud to partner with Microbot Medical and bring the LIBERTY Endovascular Robotic System to the Israeli endovascular market,” said Ravit Kremer, CEO of Medtechnica Ltd. “This agreement reflects Medtechnica’s ongoing commitment to introducing innovative medical technologies that can support physicians, advance clinical practice and improve patient care. With our strong presence and experience in the endovascular field, we look forward to working closely with Microbot Medical to introduce LIBERTY to leading hospitals and clinical teams across Israel.”

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements pertaining to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY^® Endovascular Robotic System Throughout Israel

Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.

HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company’s LIBERTY System in Israel. The Company received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, and was registered in the Israeli Medical Device Registry (AMAR) in May 2026. The Company anticipates initial orders from Medtechnica Ltd. under the agreement during the fourth quarter of 2026.

“We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel,” commented Harel Gadot, CEO, President and Chairman. “This is an important milestone for us and is expected to lead to hospitals and physicians in Israel gaining access to the LIBERTY System and achieving the same positive experiences our U.S.-based customers are enjoying. Looking ahead, we anticipate entering new markets and adding further strategic distribution partners as we continue to scale our operations, expand our manufacturing capacity, and position Microbot to meet growing demand across both U.S. and international markets.”

“We are proud to partner with Microbot Medical and bring the LIBERTY Endovascular Robotic System to the Israeli endovascular market,” said Ravit Kremer, CEO of Medtechnica Ltd. “This agreement reflects Medtechnica’s ongoing commitment to introducing innovative medical technologies that can support physicians, advance clinical practice and improve patient care. With our strong presence and experience in the endovascular field, we look forward to working closely with Microbot Medical to introduce LIBERTY to leading hospitals and clinical teams across Israel.”

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements pertaining to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY^® Endovascular Robotic System Throughout Israel

Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.

HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company’s LIBERTY System in Israel. The Company received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, and was registered in the Israeli Medical Device Registry (AMAR) in May 2026. The Company anticipates initial orders from Medtechnica Ltd. under the agreement during the fourth quarter of 2026.

“We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel,” commented Harel Gadot, CEO, President and Chairman. “This is an important milestone for us and is expected to lead to hospitals and physicians in Israel gaining access to the LIBERTY System and achieving the same positive experiences our U.S.-based customers are enjoying. Looking ahead, we anticipate entering new markets and adding further strategic distribution partners as we continue to scale our operations, expand our manufacturing capacity, and position Microbot to meet growing demand across both U.S. and international markets.”

“We are proud to partner with Microbot Medical and bring the LIBERTY Endovascular Robotic System to the Israeli endovascular market,” said Ravit Kremer, CEO of Medtechnica Ltd. “This agreement reflects Medtechnica’s ongoing commitment to introducing innovative medical technologies that can support physicians, advance clinical practice and improve patient care. With our strong presence and experience in the endovascular field, we look forward to working closely with Microbot Medical to introduce LIBERTY to leading hospitals and clinical teams across Israel.”

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements pertaining to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY^® Endovascular Robotic System Throughout Israel

Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.

HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company’s LIBERTY System in Israel. The Company received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, and was registered in the Israeli Medical Device Registry (AMAR) in May 2026. The Company anticipates initial orders from Medtechnica Ltd. under the agreement during the fourth quarter of 2026.

“We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel,” commented Harel Gadot, CEO, President and Chairman. “This is an important milestone for us and is expected to lead to hospitals and physicians in Israel gaining access to the LIBERTY System and achieving the same positive experiences our U.S.-based customers are enjoying. Looking ahead, we anticipate entering new markets and adding further strategic distribution partners as we continue to scale our operations, expand our manufacturing capacity, and position Microbot to meet growing demand across both U.S. and international markets.”

“We are proud to partner with Microbot Medical and bring the LIBERTY Endovascular Robotic System to the Israeli endovascular market,” said Ravit Kremer, CEO of Medtechnica Ltd. “This agreement reflects Medtechnica’s ongoing commitment to introducing innovative medical technologies that can support physicians, advance clinical practice and improve patient care. With our strong presence and experience in the endovascular field, we look forward to working closely with Microbot Medical to introduce LIBERTY to leading hospitals and clinical teams across Israel.”

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements pertaining to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

SUFFOLK, Va. and MOORESVILLE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Hampton Roads based TowneBank (NASDAQ: TOWN) and Mooresville based blueharbor bank (OTCQX: BLHK) (“blueharbor”), today announced the signing of a definitive merger agreement pursuant to which TowneBank will acquire blueharbor for approximately $154 million, based on TowneBank’s 10-day volume-weighted average price of $36.15 as of October 2, 2026. The proposed transaction will enhance TowneBank’s position in the greater Charlotte MSA as well as the fast-growing I-77 corridor including Mooresville and Statesville. The combination brings together blueharbor’s strong local lending and core deposit relationships with TowneBank’s broader resources, creating a stronger platform to serve customers across the region. The transaction is expected to further leverage TowneBank’s recent expansion throughout the Carolina markets.

As of June 30, 2026, blueharbor had total assets of approximately $628 million, loans of approximately $537 million, deposits of approximately $551 million, and 5 office locations.

“We are excited to welcome blueharbor and its talented team to the TowneBank family,” said G. Robert Aston, Jr., Executive Chairman of TowneBank. “blueharbor has a long history of stellar performance along with an excellent reputation across the communities it serves. This partnership reflects TowneBank’s ongoing efforts to attract experienced banking talent and build meaningful growth markets.”

“blueharbor was built on a focus upon customers, businesses and communities throughout the I-77 corridor,” said Jim Marshall, President and Chief Executive Officer of blueharbor. “We are excited to partner with TowneBank, whose commitment to community banking and serving others closely reflects our own. Our customers will benefit from TowneBank’s broader range of products, services and technology while continuing to receive the local service they value.”

“I have known Jim Marshall for years, and we are extremely proud to have him and his team as members of our TowneBank family,” said Steve Jones, President, TowneBank of the Carolinas.

Under the terms of the agreement, shareholders of blueharbor will receive $12.70 in cash and 1.0534 shares of TowneBank common stock for each share of blueharbor outstanding common stock, for an implied value of $50.78 per share based on TowneBank’s 10-day volume-weighted average price. The total consideration mix results in approximately 75% of the transaction paid in TowneBank common stock.

Following the consummation of the merger, Kelley Earnhardt Miller, Chairman of the blueharbor Board of Directors and Chief Executive Officer of JR Motorsports, will join the TowneBank family as a member of the TowneBank Corporate Board of Directors, and Jim Marshall will join the TowneBank family as Piedmont Regional President.

The definitive agreement was approved by the boards of directors of TowneBank and blueharbor. The transaction is expected to close in the first quarter of 2027 and is subject to customary closing conditions, including regulatory approval, as well as the approval of blueharbor’s shareholders.

Piper Sandler & Co. served as the financial advisor and Wachtell, Lipton, Rosen & Katz and Williams Mullen served as legal counsel to TowneBank in the transaction. D.A. Davidson & Co. served as financial advisor and Brooks, Pierce, McLendon, Humphrey & Leonard, LLP served as legal counsel to blueharbor in the transaction.

About TowneBank:
Founded in 1999, TowneBank is a company built on relationships, offering a full range of banking and other financial services, with a focus of serving others and enriching lives. Dedicated to a culture of caring, Towne values all employees and members by embracing their diverse talents, perspectives, and experiences.

Today, TowneBank operates over 70 banking offices throughout Hampton Roads and Central Virginia, Eastern and Central North Carolina, the Greenville and upstate region of South Carolina, and Charleston, South Carolina – serving as a local leader in promoting the social, cultural, and economic growth in each community. Towne offers a competitive array of business and personal banking solutions, delivered with only the highest ethical standards. Experienced local bankers providing a higher level of expertise and personal attention with local decision-making are key to the TowneBank strategy. TowneBank has grown its capabilities beyond banking to provide expertise through its affiliated companies that include Towne Wealth Management, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices RW Towne Realty, Towne 1031 Exchange, and Towne Trust Company, N.A. With total assets of $22.6 billion as of June 30, 2026, TowneBank is one of the largest banks headquartered in Virginia.

About blueharbor:
blueharbor bank is a community bank headquartered in Mooresville, North Carolina, with approximately $628 million in total assets as of June 30, 2026. Founded in 2008, blueharbor provides personal and business banking products and services through branch offices in Mooresville, Statesville and Mount Airy, as well as loan production offices in Belmont and Hickory. The bank serves customers throughout the region with a focus on long-standing relationships and local decision-making.

Media Contact:
G. Robert Aston, Jr., Executive Chairman of TowneBank, 757-638-6780
William I. Foster III, President and Chief Executive Officer of TowneBank, 757-417-6482
Jim Marshall, President and Chief Executive Officer of blueharbor bank, 704-662-7700

Investor Contact:
William B. Littreal, Chief Financial Officer of TowneBank, 757-638-6813

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead represent only the beliefs, expectations, or opinions of TowneBank and blueharbor and their respective management teams regarding future events, many of which, by their nature, are inherently uncertain and beyond the control of TowneBank and blueharbor. Forward-looking statements may be identified by the use of such words as: “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” or words of similar meaning, or future or conditional terms, such as “will,” “would,” “should,” “could,” “may,” “likely,” “probably,” or “possibly.” These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management, including statements about (i) the benefits of the transaction, including future financial and operating results, cost savings, enhancement to revenue and accretion to reported earnings that may be realized from the transaction and (ii) TowneBank’s and blueharbor’s plans, objectives, expectations and intentions and other statements contained in this communication that are not historical facts. In addition, these forward-looking statements are subject to various risks, uncertainties, estimates and assumptions with respect to future business strategies and decisions that are subject to change and difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Although TowneBank’s and blueharbor’s respective management teams believe that estimates and assumptions on which forward-looking statements are based are reasonable, such estimates and assumptions are inherently uncertain. As a result, actual results may differ materially from the anticipated results discussed in these forward-looking statements because of possible uncertainties.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) the business of blueharbor may not be successfully integrated into TowneBank, or such integration may take longer, be more difficult, time-consuming or costly to accomplish than expected; (2) the expected growth opportunities or cost savings from the transaction may not be fully realized or may take longer to realize than expected; (3) deposit attrition, operating costs, customer losses and business disruption following the transaction, including adverse effects on relationships with employees and customers, may be greater than expected; (4) the possibility that the transaction does not close when expected or at all because required regulatory, shareholder or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction); (5) the outcome of any legal proceedings that may be instituted against TowneBank or blueharbor; (6) the occurrence of any event, change, or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive merger agreement between TowneBank and blueharbor; (7) reputational risk and potential adverse reactions of TowneBank’s or blueharbor’s customers, employees or other business partners, including those resulting from the announcement or completion of the transaction; (8) the dilution caused by TowneBank’s issuance of additional shares of its capital stock in connection with the transaction; (9) the diversion of management’s attention and time from ongoing business operations and opportunities on merger-related matters; (10) economic, legislative or regulatory changes, including changes in accounting standards and changes impacting the rulemaking, supervision, examination and enforcement priorities of the federal banking agencies, that may adversely affect the businesses in which TowneBank and blueharbor are engaged; (11) competitive pressures in the banking industry that may increase significantly; (12) changes in the interest rate environment that may reduce margins and/or the volumes and values of loans made or held as well as the value of other financial assets held; (13) an unforeseen outflow of cash or deposits or an inability to access the capital markets, which could jeopardize TowneBank’s or blueharbor’s overall liquidity or capitalization; (14) changes in the creditworthiness of customers and the possible impairment of the collectability of loans; (15) insufficiency of TowneBank’s or blueharbor’s allowance for credit losses due to market conditions, inflation, changing interest rates or other factors; (16) adverse developments in the financial industry generally, responsive measures to mitigate and manage such developments, related supervisory and regulatory actions and costs, and related impacts on customer and client behavior; (17) general economic conditions, either nationally or regionally, that may be less favorable than expected, resulting in, among other things, a deterioration in credit quality and/or a reduced demand for credit or other services; (18) geopolitical instability, including wars, conflicts, trade restrictions and tariffs, civil unrest, and terrorist attacks and the potential impact, directly or indirectly, on TowneBank’s or blueharbor’s business; (19) the effects of weather-related or natural disasters, which may negatively affect TowneBank’s or blueharbor’s operations and/or TowneBank’s or blueharbor’s loan portfolio and increase the cost of conducting business; (20) public health events (such as the COVID-19 pandemic) and governmental and societal responses to them; (21) the introduction of new lines of business or new products and services; (22) cybersecurity threats or attacks, whether directed at TowneBank or blueharbor or at vendors or other third parties with which TowneBank or blueharbor interact; (23) the implementation of new technologies, and the ability to develop and maintain reliable electronic systems; (24) changes in business conditions; (25) changes in the securities market; and (26) changes in the local economies with regard to TowneBank’s and blueharbor’s respective market areas.

Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in TowneBank’s reports filed with the Federal Deposit Insurance Corporation (“FDIC”). TowneBank and blueharbor undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

Important Information and Where to Find It

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of TowneBank or a solicitation of any vote or approval. blueharbor will deliver a definitive proxy statement/offering circular to its shareholders seeking approval of the merger and related matters. In addition, TowneBank may file other relevant documents concerning the proposed merger with the FDIC. Before making any voting or investment decision, investors and security holders are urged to read the proxy statement/offering circular and any other relevant documents to be filed with the FDIC in connection with the proposed transaction because they contain important information about TowneBank, blueharbor, and the proposed merger.

Shareholders are also urged to carefully review TowneBank’s public filings with the FDIC, including, but not limited to, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and proxy statements. Free copies of filings containing information about TowneBank may be obtained after their filing at the FDIC’s website (https://www.fdic.gov). The documents described above also may be obtained by directing a request by telephone or mail to TowneBank, 6001 Harbour View Boulevard, Suffolk, Virginia 23435, Attention: Investor Relations (telephone: (757) 638-6794), or by accessing TowneBank’s website at https://townebank.com under “Investor Relations.” In addition, free copies of the definitive proxy statement/offering circular, when available, may be obtained by directing a request by telephone or mail to blueharbor bank, P.O. Box 3546, 106 Corporate Park Dr., Mooresville, North Carolina 28117, Attention: Jim Marshall (telephone: (704) 662-7700) or by accessing blueharbor’s website at https://www.blueharborbank.com under “Newsroom.” The information on TowneBank’s website and blueharbor’s website is not, and shall not be deemed to be, a part of this press release or incorporated into other filings TowneBank makes with the FDIC.

Participants in the Solicitation

TowneBank, blueharbor, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of blueharbor in connection with the proposed merger. Information about the directors and executive officers of blueharbor and TowneBank and other persons who may be deemed participants in the solicitation, including their interests in the merger, will be included in the proxy statement/offering circular when it becomes available. Additional information about the directors and executive officers of TowneBank can be found in TowneBank’s proxy statement in connection with its annual meeting of shareholders, filed with the FDIC on April 10, 2026. Additional information about the directors and executive officers of blueharbor can be found in blueharbor’s proxy statement in connection with its annual meeting of shareholders, as sent previously to blueharbor’s shareholders on or about April 6, 2026.

SUFFOLK, Va. and MOORESVILLE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Hampton Roads based TowneBank (NASDAQ: TOWN) and Mooresville based blueharbor bank (OTCQX: BLHK) (“blueharbor”), today announced the signing of a definitive merger agreement pursuant to which TowneBank will acquire blueharbor for approximately $154 million, based on TowneBank’s 10-day volume-weighted average price of $36.15 as of October 2, 2026. The proposed transaction will enhance TowneBank’s position in the greater Charlotte MSA as well as the fast-growing I-77 corridor including Mooresville and Statesville. The combination brings together blueharbor’s strong local lending and core deposit relationships with TowneBank’s broader resources, creating a stronger platform to serve customers across the region. The transaction is expected to further leverage TowneBank’s recent expansion throughout the Carolina markets.

As of June 30, 2026, blueharbor had total assets of approximately $628 million, loans of approximately $537 million, deposits of approximately $551 million, and 5 office locations.

“We are excited to welcome blueharbor and its talented team to the TowneBank family,” said G. Robert Aston, Jr., Executive Chairman of TowneBank. “blueharbor has a long history of stellar performance along with an excellent reputation across the communities it serves. This partnership reflects TowneBank’s ongoing efforts to attract experienced banking talent and build meaningful growth markets.”

“blueharbor was built on a focus upon customers, businesses and communities throughout the I-77 corridor,” said Jim Marshall, President and Chief Executive Officer of blueharbor. “We are excited to partner with TowneBank, whose commitment to community banking and serving others closely reflects our own. Our customers will benefit from TowneBank’s broader range of products, services and technology while continuing to receive the local service they value.”

“I have known Jim Marshall for years, and we are extremely proud to have him and his team as members of our TowneBank family,” said Steve Jones, President, TowneBank of the Carolinas.

Under the terms of the agreement, shareholders of blueharbor will receive $12.70 in cash and 1.0534 shares of TowneBank common stock for each share of blueharbor outstanding common stock, for an implied value of $50.78 per share based on TowneBank’s 10-day volume-weighted average price. The total consideration mix results in approximately 75% of the transaction paid in TowneBank common stock.

Following the consummation of the merger, Kelley Earnhardt Miller, Chairman of the blueharbor Board of Directors and Chief Executive Officer of JR Motorsports, will join the TowneBank family as a member of the TowneBank Corporate Board of Directors, and Jim Marshall will join the TowneBank family as Piedmont Regional President.

The definitive agreement was approved by the boards of directors of TowneBank and blueharbor. The transaction is expected to close in the first quarter of 2027 and is subject to customary closing conditions, including regulatory approval, as well as the approval of blueharbor’s shareholders.

Piper Sandler & Co. served as the financial advisor and Wachtell, Lipton, Rosen & Katz and Williams Mullen served as legal counsel to TowneBank in the transaction. D.A. Davidson & Co. served as financial advisor and Brooks, Pierce, McLendon, Humphrey & Leonard, LLP served as legal counsel to blueharbor in the transaction.

About TowneBank:
Founded in 1999, TowneBank is a company built on relationships, offering a full range of banking and other financial services, with a focus of serving others and enriching lives. Dedicated to a culture of caring, Towne values all employees and members by embracing their diverse talents, perspectives, and experiences.

Today, TowneBank operates over 70 banking offices throughout Hampton Roads and Central Virginia, Eastern and Central North Carolina, the Greenville and upstate region of South Carolina, and Charleston, South Carolina – serving as a local leader in promoting the social, cultural, and economic growth in each community. Towne offers a competitive array of business and personal banking solutions, delivered with only the highest ethical standards. Experienced local bankers providing a higher level of expertise and personal attention with local decision-making are key to the TowneBank strategy. TowneBank has grown its capabilities beyond banking to provide expertise through its affiliated companies that include Towne Wealth Management, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices RW Towne Realty, Towne 1031 Exchange, and Towne Trust Company, N.A. With total assets of $22.6 billion as of June 30, 2026, TowneBank is one of the largest banks headquartered in Virginia.

About blueharbor:
blueharbor bank is a community bank headquartered in Mooresville, North Carolina, with approximately $628 million in total assets as of June 30, 2026. Founded in 2008, blueharbor provides personal and business banking products and services through branch offices in Mooresville, Statesville and Mount Airy, as well as loan production offices in Belmont and Hickory. The bank serves customers throughout the region with a focus on long-standing relationships and local decision-making.

Media Contact:
G. Robert Aston, Jr., Executive Chairman of TowneBank, 757-638-6780
William I. Foster III, President and Chief Executive Officer of TowneBank, 757-417-6482
Jim Marshall, President and Chief Executive Officer of blueharbor bank, 704-662-7700

Investor Contact:
William B. Littreal, Chief Financial Officer of TowneBank, 757-638-6813

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead represent only the beliefs, expectations, or opinions of TowneBank and blueharbor and their respective management teams regarding future events, many of which, by their nature, are inherently uncertain and beyond the control of TowneBank and blueharbor. Forward-looking statements may be identified by the use of such words as: “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” or words of similar meaning, or future or conditional terms, such as “will,” “would,” “should,” “could,” “may,” “likely,” “probably,” or “possibly.” These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management, including statements about (i) the benefits of the transaction, including future financial and operating results, cost savings, enhancement to revenue and accretion to reported earnings that may be realized from the transaction and (ii) TowneBank’s and blueharbor’s plans, objectives, expectations and intentions and other statements contained in this communication that are not historical facts. In addition, these forward-looking statements are subject to various risks, uncertainties, estimates and assumptions with respect to future business strategies and decisions that are subject to change and difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Although TowneBank’s and blueharbor’s respective management teams believe that estimates and assumptions on which forward-looking statements are based are reasonable, such estimates and assumptions are inherently uncertain. As a result, actual results may differ materially from the anticipated results discussed in these forward-looking statements because of possible uncertainties.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) the business of blueharbor may not be successfully integrated into TowneBank, or such integration may take longer, be more difficult, time-consuming or costly to accomplish than expected; (2) the expected growth opportunities or cost savings from the transaction may not be fully realized or may take longer to realize than expected; (3) deposit attrition, operating costs, customer losses and business disruption following the transaction, including adverse effects on relationships with employees and customers, may be greater than expected; (4) the possibility that the transaction does not close when expected or at all because required regulatory, shareholder or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction); (5) the outcome of any legal proceedings that may be instituted against TowneBank or blueharbor; (6) the occurrence of any event, change, or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive merger agreement between TowneBank and blueharbor; (7) reputational risk and potential adverse reactions of TowneBank’s or blueharbor’s customers, employees or other business partners, including those resulting from the announcement or completion of the transaction; (8) the dilution caused by TowneBank’s issuance of additional shares of its capital stock in connection with the transaction; (9) the diversion of management’s attention and time from ongoing business operations and opportunities on merger-related matters; (10) economic, legislative or regulatory changes, including changes in accounting standards and changes impacting the rulemaking, supervision, examination and enforcement priorities of the federal banking agencies, that may adversely affect the businesses in which TowneBank and blueharbor are engaged; (11) competitive pressures in the banking industry that may increase significantly; (12) changes in the interest rate environment that may reduce margins and/or the volumes and values of loans made or held as well as the value of other financial assets held; (13) an unforeseen outflow of cash or deposits or an inability to access the capital markets, which could jeopardize TowneBank’s or blueharbor’s overall liquidity or capitalization; (14) changes in the creditworthiness of customers and the possible impairment of the collectability of loans; (15) insufficiency of TowneBank’s or blueharbor’s allowance for credit losses due to market conditions, inflation, changing interest rates or other factors; (16) adverse developments in the financial industry generally, responsive measures to mitigate and manage such developments, related supervisory and regulatory actions and costs, and related impacts on customer and client behavior; (17) general economic conditions, either nationally or regionally, that may be less favorable than expected, resulting in, among other things, a deterioration in credit quality and/or a reduced demand for credit or other services; (18) geopolitical instability, including wars, conflicts, trade restrictions and tariffs, civil unrest, and terrorist attacks and the potential impact, directly or indirectly, on TowneBank’s or blueharbor’s business; (19) the effects of weather-related or natural disasters, which may negatively affect TowneBank’s or blueharbor’s operations and/or TowneBank’s or blueharbor’s loan portfolio and increase the cost of conducting business; (20) public health events (such as the COVID-19 pandemic) and governmental and societal responses to them; (21) the introduction of new lines of business or new products and services; (22) cybersecurity threats or attacks, whether directed at TowneBank or blueharbor or at vendors or other third parties with which TowneBank or blueharbor interact; (23) the implementation of new technologies, and the ability to develop and maintain reliable electronic systems; (24) changes in business conditions; (25) changes in the securities market; and (26) changes in the local economies with regard to TowneBank’s and blueharbor’s respective market areas.

Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in TowneBank’s reports filed with the Federal Deposit Insurance Corporation (“FDIC”). TowneBank and blueharbor undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

Important Information and Where to Find It

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of TowneBank or a solicitation of any vote or approval. blueharbor will deliver a definitive proxy statement/offering circular to its shareholders seeking approval of the merger and related matters. In addition, TowneBank may file other relevant documents concerning the proposed merger with the FDIC. Before making any voting or investment decision, investors and security holders are urged to read the proxy statement/offering circular and any other relevant documents to be filed with the FDIC in connection with the proposed transaction because they contain important information about TowneBank, blueharbor, and the proposed merger.

Shareholders are also urged to carefully review TowneBank’s public filings with the FDIC, including, but not limited to, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and proxy statements. Free copies of filings containing information about TowneBank may be obtained after their filing at the FDIC’s website (https://www.fdic.gov). The documents described above also may be obtained by directing a request by telephone or mail to TowneBank, 6001 Harbour View Boulevard, Suffolk, Virginia 23435, Attention: Investor Relations (telephone: (757) 638-6794), or by accessing TowneBank’s website at https://townebank.com under “Investor Relations.” In addition, free copies of the definitive proxy statement/offering circular, when available, may be obtained by directing a request by telephone or mail to blueharbor bank, P.O. Box 3546, 106 Corporate Park Dr., Mooresville, North Carolina 28117, Attention: Jim Marshall (telephone: (704) 662-7700) or by accessing blueharbor’s website at https://www.blueharborbank.com under “Newsroom.” The information on TowneBank’s website and blueharbor’s website is not, and shall not be deemed to be, a part of this press release or incorporated into other filings TowneBank makes with the FDIC.

Participants in the Solicitation

TowneBank, blueharbor, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of blueharbor in connection with the proposed merger. Information about the directors and executive officers of blueharbor and TowneBank and other persons who may be deemed participants in the solicitation, including their interests in the merger, will be included in the proxy statement/offering circular when it becomes available. Additional information about the directors and executive officers of TowneBank can be found in TowneBank’s proxy statement in connection with its annual meeting of shareholders, filed with the FDIC on April 10, 2026. Additional information about the directors and executive officers of blueharbor can be found in blueharbor’s proxy statement in connection with its annual meeting of shareholders, as sent previously to blueharbor’s shareholders on or about April 6, 2026.